Why Is Repare Therapeutics Stock Trading Lower On Friday?
Why Is Repare Therapeutics Stock Trading Lower On Friday?
The most common adverse event was anemia (26.9%, Grade 3).On Thursday, Repare Therapeutics Inc (NASDAQ:RPTX) revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers.
週四，Repare Therapeutics Inc（納斯達克股票代碼：RPTX）公佈了其MYTHIC 1期婦科擴張試驗的數據，該試驗評估了lunersetib和camonsertib（Lunre+Camo）聯合治療子宮內膜癌和含有月球敏感生物標誌物的鉑耐藥卵巢癌（PROC）。
As of the data cut-off date of November 14, 51 evaluable patients were enrolled in the gynecologic cancer expansion cohort of the MYTHIC trial.
截至11月14日的數據截止日，MYTHIC試驗的婦科癌症擴展隊列招收了51名可評估的患者。
Across all tumor types treated at the optimized RP2D (n=67), Lunre+Camo therapy showed a favorable and differentiated tolerability profile compared to current and emerging therapies.
在經過優化的RP2D（n=67）治療的所有腫瘤類型中，與當前和新興療法相比，Lunre+Camo療法表現出良好的差異化耐受性。
The most common adverse event was anemia (26.9%, Grade 3).
最常見的不良事件是貧血（26.9％，3級）。
Key Cohort Clinical Findings
關鍵隊列臨床發現
Key efficacy outcomes from 27 evaluable patients with endometrial cancer show:
27名可評估的子宮內膜癌患者的主要療效結果顯示：
- Overall response rate was 25.9% (confirmed ORR in 5 out of 7 patients).
- Clinical benefit was observed in 48.1% of patients, with responses frequently occurring after 12 weeks or more.
- At the 24-week landmark analysis, nearly half of patients experienced durable clinical benefit (24-week PFS [PFS24w] = 43%.
- 總體緩解率爲25.9％（7名患者中有5名確診了ORR）。
- 在48.1％的患者中觀察到臨床益處，反應通常在12周或更長時間後出現。
- 在爲期24周的里程碑分析中，將近一半的患者獲得了持久的臨床益處（24周PFS [pfs24W] = 43％）。
Key efficacy outcomes in 24 evaluable Platinum-Resistant Ovarian Cancer patients show:
24名可評估的耐鉑卵巢癌患者的主要療效結果顯示：
- Overall response rate was 37.5% (confirmed ORR in 4 out of 9 patients).
- Clinical benefit was observed in 79% of patients.
- PFS at the 24-week landmark analysis was PFS24w = 45%.
- 總體緩解率爲37.5％（9名患者中有4名確診了ORR）。
- 在79％的患者中觀察到臨床益處。
- 在爲期24周的里程碑分析中，PFS爲pfs24w = 45％。
Repare has consulted with the FDA and the European Medicines Agency, who have guided the company's registrational development plans for Lunre+Camo in gynecologic tumors.
Repare已經諮詢了美國食品藥品管理局和歐洲藥品管理局，後者指導了該公司在婦科腫瘤中的Lunre+Camo的註冊開發計劃。
Repare plans to provide the final Phase 3 trial protocols for regulatory clearance imminently and intends to start the first Phase 3 Lunre+Camo trial in endometrial cancer in the second half of 2025.
Repare計劃立即提供最終的3期試驗方案以供監管部門批准，並打算在2025年下半年開始子宮內膜癌的首項3期Lunre+Camo試驗。
Additionally, the company expects to initiate a small contribution of components trial in up to 40 patients with endometrial cancer in the first quarter of 2025.
此外，該公司預計將在2025年第一季度啓動對多達40名子宮內膜癌患者進行少量成分捐贈試驗。
Price Action: RPTX stock is down 52.4% at $1.89 at last check Friday.
價格走勢：週五最後一次檢查時，RPTX股價下跌52.4％，至1.89美元。
- CF Industries Carbon Capture Credits EBITDA Potential Could Be As High As $50 Million: Analyst
- 分析師：CF Industries碳捕集信貸的息稅折舊攤銷前利潤潛力可能高達5000萬美元
Photo via Shutterstock.
照片來自 Shutterstock。
